PHARMACOGENETICS OF RISPERIDONE IN CHILDREN WITH PDD

利培酮在 PDD 儿童中的药物遗传学

• 批准号: 7374603
• 负责人: MICHAEL George AMAN
• 金额: $ 0.26万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374603
• 关键词: PHARMACOGENETICS; RISPERIDONE; CHILDREN; PDD

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The ultimate goal of these experiments is to detect unique patterns of allelic variations that will identify children who may experience either abnormal risperidone PK profiles, and/or subsequent suboptimal response or drug toxicity from those who will not experience these problems.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这些实验的最终目的是检测等位基因变异的独特模式，从而识别可能出现利培酮PK谱异常和/或随后的次优反应或药物毒性的儿童，而这些儿童不会出现这些问题。